News Help Institutional access
Back to results
Bibliographic record · Consultation and access
Artículo

Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer

Jing Lü et al · Shanghai Chinese Clinical Medicine Press Co., Ltd · 2026

Open access available
Quick overview. Review the resource’s basic details, then access the content using the main button. This page shows only the information needed to identify, cite, and open the work.
Author / responsible party
Jing Lü et al
Publisher
Shanghai Chinese Clinical Medicine Press Co., Ltd
Year
2026
ISSN
1008-6358
ISSN
1008-6358
Language
English

Resource access

Open the content from the main option or choose another available source.

DOAJ DOAJ Articles
Entrar por DOAJ
Main access

Open access available

Recurso identificado como acceso abierto, sin confirmar automáticamente si es texto completo directo.
Open resource

Summary

Descripción general del contenido del recurso.

Lutetium-177 (177Lu)-prostate specific membrane antigen (PSMA)-617 is a small-molecule radioligand therapy (RLT) drug targeting PSMA. By selectively delivering the β－ radiation emitted by 177Lu to PSMA-positive prostate cancer cells, it induces tumor cell death. The agent has been approved in multiple nations and regions for the treatment of PSMA-positive metastatic castration-resistant prostate cancer, thereby expanding therapeutic options for this patient population. This review outlines the development, pharmacological properties, and current clinical applications of 177Lu-PSMA-617, aiming to provide a theoretical basis for the clinical practice of RLT in prostate cancer treatment.

How to cite

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, J. L. E. (2026). Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer. https://doi.org/10.12025/j.issn.1008-6358.2025.20251534

MLA

al, Jing Lü et. "Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer." 2026. https://doi.org/10.12025/j.issn.1008-6358.2025.20251534.

Chicago

al, Jing Lü et. 2026. "Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer.". https://doi.org/10.12025/j.issn.1008-6358.2025.20251534.

Harvard

al, J. L. E. 2026, Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer, Shanghai Chinese Clinical Medicine Press Co, Ltd, available at: https://doi.org/10.12025/j.issn.1008-6358.2025.20251534 [Accessed 8 Aug. 2026].

Share and print

Save the record, copy its permanent link, or print it as a PDF.

Export reference

You can export the record in common formats for use in a reference manager.

RIS BibTeX

Resource details

Bibliographic information to help confirm that this is the correct material.

Title
Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer
Author / contributors
Jing Lü et al
Publisher
Shanghai Chinese Clinical Medicine Press Co., Ltd
Publication year
2026
ISSN
1008-6358
ISSN
1008-6358
Language
English

Subjects

Explore related resources through these subjects.

prostate cancer; radioligand therapy; prostate specific membrane antigen; lutetium-177; 177lu-psma-617
Copied